Literature DB >> 26593145

Consequences of Sarcoidosis.

Marjolein Drent1, Bert Strookappe2, Elske Hoitsma3, Jolanda De Vries4.   

Abstract

Sarcoidosis is a multisystem disorder of unknown cause(s). Less specific disabling symptoms, including fatigue and physical impairments, may have a major influence on the daily activities and the social and professional lives of the patients, resulting in a reduced quality of life. A multidisciplinary approach focusing on somatic and psychosocial aspects is recommended. Patients self-perceived knowledge about the importance of exercise and lifestyle should be improved. Developing the most appropriate therapeutic approach for sarcoidosis requires careful consideration of the possible impact of fatigue, small fiber neuropathy related symptoms, pain, cognitive functioning, and coping strategies. Personalized medicine and appropriate communication are beneficial.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognitive impairment; Depressive symptoms; Exercise limitation; Fatigue; Pain; Quality of life; Rehabilitation; Sarcoidosis; Small fiber neuropathy

Mesh:

Year:  2015        PMID: 26593145     DOI: 10.1016/j.ccm.2015.08.013

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  21 in total

1.  Physical Activity and Fatigue in Patients with Sarcoidosis.

Authors:  Thomas Bahmer; Henrik Watz; Maria Develaska; Benjamin Waschki; Klaus F Rabe; Helgo Magnussen; Detlef Kirsten; Anne-Marie Kirsten
Journal:  Respiration       Date:  2017-11-09       Impact factor: 3.580

2.  Quality of Life of Couples Living with Sarcoidosis.

Authors:  Mareye Voortman; Celine M R Hendriks; Paul Lodder; Marjolein Drent; Jolanda De Vries
Journal:  Respiration       Date:  2019-08-22       Impact factor: 3.580

3.  Cognitive Difficulties and Health-Related Quality of Life in Sarcoidosis: An Analysis of the GRADS Cohort.

Authors:  Karin F Hoth; Jacob Simmering; Anna Croghan; Nabeel Y Hamzeh
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

4.  Benefits of Physical Training in Sarcoidosis.

Authors:  Bert Strookappe; Jeff Swigris; Jolanda De Vries; Marjon Elfferich; Ton Knevel; Marjolein Drent
Journal:  Lung       Date:  2015-08-19       Impact factor: 2.584

5.  Treatment of Sarcoidosis in US Rheumatology Practices: Data From the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry.

Authors:  Nevin Hammam; Michael Evans; Esi Morgan; Andreas Reimold; Christine Anastasiou; Julia L Kay; Jinoos Yazdany; Gabriela Schmajuk
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-28       Impact factor: 4.794

6.  Everyday cognitive failure in patients suffering from neurosarcoidosis.

Authors:  Mareye Voortman; Jolanda De Vries; Celine M R Hendriks; Marjon D P Elfferich; Petal A H M Wijnen; Marjolein Drent
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 7.  Management of neurosarcoidosis: a clinical challenge.

Authors:  Mareye Voortman; Marjolein Drent; Robert P Baughman
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

8.  Quantification of small fiber pathology in patients with sarcoidosis and chronic pain using cornea confocal microscopy and skin biopsies.

Authors:  Linda Cj Oudejans; Marieke Niesters; Michael Brines; Albert Dahan; Monique van Velzen
Journal:  J Pain Res       Date:  2017-08-26       Impact factor: 3.133

9.  Feasibility, utility and symptom impact of modified mindfulness training in sarcoidosis.

Authors:  Lesley Ann Saketkoo; Aryn Karpinski; Jessica Young; Ryan Adell; McCall Walker; Tamarin Hennebury; Melissa Wickremasinghe; Anne-Marie Russell
Journal:  ERJ Open Res       Date:  2018-05-08

10.  Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners.

Authors:  C C Moor; M J G van Manen; P M van Hagen; J R Miedema; L M van den Toorn; Y Gür-Demirel; A P C Berendse; J A M van Laar; M S Wijsenbeek
Journal:  Lung       Date:  2018-08-07       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.